

PROVIDER QUICK POINTS

PROVIDER INFORMATION



February 9, 2022

Commercial Pharmacy Benefit Exclusion for Apretude, Tezspire™, and Vyvgart™

Effective March 1, 2022, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Apretude (cabotegravir extended release) injectable suspension for intramuscular use
Tezspire™ (tezepelumab-ekko) injection for subcutaneous use
Vyvgart™ (efgartigimod alfa-fcab) injection for intravenous use

Products Impacted

This applies to commercial line of business.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.